Steven C. Miller Named Chief Commercialization Officer at Senior Scientific Subsidiary of Manhattan Scientifics
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Aug 28, 2012--Manhattan Scientifics (OTCBB: MHTX) announced today that its Senior Scientific subsidiary has named Steven C. Miller, Ph.D. to the position of Chief Commercialization Officer.
Senior Scientific is developing and commercializing technology developed by Dr. Edward R. Flynn. Senior Scientifics’ nanotechnology and imaging technology can detect tumors and metastases much earlier than currently possible and can measure and locate tumors more precisely than ever before.
As Chief Commercialization Officer, Dr. Miller will lead the manufacturing and commercialization of the targeted nanoparticles for the detection of biomarkers important in diseases, launch of the imaging technology into preclinical markets, and help position Senior Scientific’s technology for clinical applications.
Dr. Miller was most recently President and CEO of On-Target Biotech Consulting, Inc., a privately owned corporation providing consulting services focused on the commercialization of innovative technologies for the pharmaceutical and biotechnology industries. He has broad science and management experience in the discovery and development of biopharmaceuticals, antibodies, nanoparticles, novel cell analyses and small animal imaging technologies.
Senior Scientifics President Gerald Grafe said, “Steve has a world-class understanding of the commercial landscape in biopharmaceuticals, medical diagnostics, and use of nanoparticles for small animal imaging applications. He adds strong science and executive leadership to the team and has the experience to bring new and innovative technologies to market. His experience is a perfect complement to our team and will greatly accelerate our progress.” Dr. Miller said, “Ed and the Senior Scientific team have developed a game-changing technology for the noninvasive detection and imaging of early stage cancers expressing a biomarker using superparamagnetic nanoparticles as the imaging agent. It is an exciting time to join the team as we develop and implement a broad commercialization strategy providing for a family of product solutions ranging from preclinical research to clinical trials.” Manhattan CEO Manny Tsoupanarias said, "We are convinced that the Senior Scientific technology will dramatically improve detection and treatment in a wide range of cancers. Steve has exactly the science and business experience that Senior Scientific needs to advance our products into the biopharmaceutical and biotechnology markets. His experience in developing and implementing strategies focused on enhancing value and building strong customer partnerships will accelerate our efforts advancing this technology into products to address unmet medical needs.” Dr. Miller has held several commercial management positions responsible for the launch of new technologies. At Zymera Inc., as Chief Commercialization Officer he led the commercialization of a novel self-illuminating quantum dot nanoparticle technology developed for preclinical imaging applications.
At MDS Analytical Technologies (now Molecular Devices) he led the Research and Technology team of 20 people. He was VP Biology with Blueshift Biotechnologies, Inc. (now part of Molecular Devices) where he was responsible for the commercial expansion and implementation of a novel laser-scanning platform for high throughput quantitative fluorescence-based array, bead, cell, and small organism imaging applications.
He was Chief Science Officer with Labcyte, LLC, a laboratory automation instrument and consumables provider. At Abgenix Inc., he led a group in Assay Development responsible for implementing new technology platforms to accelerate the discovery of human antibody therapeutics. Prior to this, he was Director of Scientific Affairs and Applications Support for Biometric Imaging (a Becton Dickinson Company) where he managed scientific marketing evaluations of a novel laser scanning microvolume cytometer developed for FDA-cleared diagnostic applications. At SRI International he was Director of the Signal Transduction Program and Principal Investigator for research funded by government grants, contracts, and biotechnology companies. He has published over 70 papers and abstracts, and co-authored patents (published and pending). Education: NIH Postdoctoral Fellow, 1986, Stanford University School of Medicine; Ph.D. in microbiology/cell biology, 1983, University of Kansas School of Medicine; B.G.S. in biochemistry, 1976, University of Kansas.
About Manhattan Scientifics Manhattan Scientifics Inc. ( www.mhtx.com ) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.
About Senior Scientifics Senior Scientific, LLC ( www.seniorscientific.com ) is a New Mexico Company with research facilities located at the University of New Mexico Science and Technology Park in Albuquerque, New Mexico and longstanding relationships with the University of New Mexico Health Sciences Center, the Los Alamos National Laboratories, and the Center for Integrated Nanotechnology (CINT) at Sandia National Laboratory. The Company’s focus is in the emerging field of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, and is the leader in a technology called Nanomagnetic Relaxometry (“NanoMRX”). Its proprietary technologies and methods employ magnetic nanoparticles targeted towards cells associated with cancer and other diseases, and detect those cells tagged with magnetic nanoparticles through sophisticated magnetic sensors.
Forward-looking statement This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.CONTACT: Manhattan Scientifics, Inc.
Investor Relations: Marvin Maslow, 917-923-3300 email@example.com or U.S. & Canadian Investor Relations Hawk Associates Frank Hawkins, 305-451-1888 firstname.lastname@example.org or European Contact: Herbert Strauss, +43-316-296-316 email: herbert"at"eu-ir.com or Info@SeniorScientific.com www.mhtx.com Senior Scientific LLC www.seniorscientific.com KEYWORD: UNITED STATES NORTH AMERICA NEW MEXICO NEW YORK INDUSTRY KEYWORD: TECHNOLOGY NANOTECHNOLOGY HEALTH BIOTECHNOLOGY HOSPITALS OTHER HEALTH RESEARCH OTHER SCIENCE SCIENCE SOURCE: Manhattan Scientifics Copyright Business Wire 2012 PUB: 08/28/2012 09:30 AM/DISC: 08/28/2012 09:30 AM http://www.businesswire.com/news/home/20120828005933/